Effectiveness of a cognitive behavioral intervention in patients with medically unexplained symptoms: Cluster randomized trial by Lápez-García-Franco, Alberto et al.
López-García-Franco et al. BMC Family Practice 2012, 13:35
http://www.biomedcentral.com/1471-2296/13/35STUDY PROTOCOL Open AccessEffectiveness of a cognitive behavioral
intervention in patients with medically
unexplained symptoms: cluster randomized trial
Alberto López-García-Franco1*, Mª. Isabel del-Cura-González2,3, Luis Caballero-Martinez4, Teresa Sanz-Cuesta2,
Marta Isabel Díaz-García5, Mª. Teresa Rodriguez-Monje6, Marcela Chahua7, Inmaculada Muñoz-Sanchez8,
Dolores Serrano-González6, Teresa Rollán-Llanderas9, Esther Nieto-Blanco10, Liliana Losada-Cucco6,
Fernando Caballero-Martínez11, Nuria Sanz-García1, Belén Pose-García1, Montserrat Jurado-Sueiro12,
Manuela Luque Rey13, Francisca García de Blas González1, Mª. Angeles Miguel Abanto13, Teresa Sanz Bayona13,
Rafaela Ayllón-Camargo6, Inmaculada Santamaría Lopez6, María Luisa Santiago Hernando12,
Rosario Beltran-Alvarez14, Ana Isabel Aguilar-Gutierrez14, Jose Luis Mota-Rodriguez14, Rafaél Cosculluela-Pueyo14,
Teresa López-Martín-Aragón13, Rosa Bonilla-Sanchez15, Mª. Carmen Aritieda-González-Granda15,
Raquel Razola-Rincón15, Mª. Angeles Sanchez-de-la-Ventana16, Concepción Martinez-Guinea16, Luis Huerta-Galindo16,
Ana Belén Barrio-Ovalle16, Susana Miguel-Martín16, Paz Portero-Fraile16, Higinio Pensado-Freire17,
Mª Luisa Herrera-Garcia18, Amaya Azcoaga-Lorenzo1, Inés Gómez-García19, Nuria Llamas-Sandino19,
Isabel López-Borja19, Hortensia Maldonado-Castro19, Patricia Lumbreras-Villarán1 and Carlos Ascanio-Durán1Abstract
Background: Medically unexplained symptoms are an important mental health problem in primary care and generate
a high cost in health services.
Cognitive behavioral therapy and psychodynamic therapy have proven effective in these patients. However, there are
few studies on the effectiveness of psychosocial interventions by primary health care. The project aims to determine
whether a cognitive-behavioral group intervention in patients with medically unexplained symptoms, is more effective
than routine clinical practice to improve the quality of life measured by the SF-12 questionary at 12 month.
Methods/design: This study involves a community based cluster randomized trial in primary healthcare centres in
Madrid (Spain). The number of patients required is 242 (121 in each arm), all between 18 and 65 of age with medically
unexplained symptoms that had seeked medical attention in primary care at least 10 times during the previous year.
The main outcome variable is the quality of life measured by the SF-12 questionnaire on Mental Healthcare. Secondary
outcome variables include number of consultations, number of drug (prescriptions) and number of days of sick leave
together with other prognosis and descriptive variables. Main effectiveness will be analyzed by comparing the
percentage of patients that improve at least 4 points on the SF-12 questionnaire between intervention and control
groups at 12 months. All statistical tests will be performed with intention to treat. Logistic regression with random
effects will be used to adjust for prognostic factors. Confounding factors or factors that might alter the effect recorded
will be taken into account in this analysis.* Correspondence: alopez.gapm09@salud.madrid.org
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http://www.biomedcentral.com/1471-2296/13/35Discussion: This study aims to provide more insight to address medically unexplained symptoms, highly prevalent
in primary care, from a quantitative methodology. It involves intervention group conducted by previously trained
nursing staff to diminish the progression to the chronicity of the symptoms, improve quality of life, and reduce
frequency of medical consultations.
Trial registration: The trial was registered with ClinicalTrials.gov, number NCT01484223 [http://ClinicalTrials.gov].Background
The somatoform disorders
Somatic symptoms are those symptoms that cannot be
medically explained and when they only have a somatic
nature, they are referred to as somatoform disorders.
They can be found in a healthy population as well as in
patients with psychiatric disorders; and they represent
an important reason for doctor’s examination in primary
care. This group of disorders includes [1]: disorder caused
by somatization (including 8 symptoms), syndrome by
abbreviated somatization (4 symptoms throughout the
whole life in men or 6 in women), or multi-somatoform
disorder (three or more important symptoms without med-
ical explanation and more than 2 years of development).
The diagnosis of these disorders is difficult. The classifi-
cation of somatoform disorders in CIE-10 and in DSM IV
is shown in Table 1.
Today, there is debate about the suitability of somatiza-
tion disorder differ from other functional symptoms. It is
estimated that 75% of patients with medically unexplained
symptoms (MUS) and over-the health system does not meet
the diagnostic criteria for abbreviated somatization syn-
drome [2]. While somatization disorder affecting 0.4% of
the population, all somatoform disorders are between 20
and 30% of consultations in primary care [2]. When the
patient has at least one symptom in 5 specific areas (pain,
fatigue, irritable bowel syndrome, somatic symptoms of
anxiety or somatic symptoms of depression) and protracted
(at least 4 consultations in a year) some authors recom-
mend defining it as MUS [3].
In a clinical series in the USA, a clear organic cause was
not found among the 20% - 84% of the patients that went
to the family physician with throbs, thoracic pain, mi-
graine, fatigue or sickness [4]. On the other hand, up to
75% of the patients with major depressive disorders or
anxiety attacks go to their family doctors only because of
the somatic symptoms they show [5].
A study in Spain [6] shows that 34.5% of patients who
visit for the first time to their family physician suffer
from for somatic symptoms. Most of these symptoms are
severe, and a percentage end up having a somatization
disorder or undifferentiated somatization disorder.
The somatoform disorders are an excluding diagnosis
that forces to carry out a significant number of comple-
mentary tests and derivations to the second and third
level.The somatoform disorders are highly prevalent in pri-
mary care [2]. It is estimated that this kind of patient uses
up 14 times more resources in outpatient, and 6 times
more expenses under hospital regimen [7].
Approach to the somatoform disorders
There is consensus that the approach to the different fea-
tures of somatoform disorders should be carried out with
similar interventions; without indicating specific therapies
for each of the aforementioned manifestations [8].
There is data on the usefulness of the implementation
of Good Clinical Practice (GCP) criteria (Table 2), by
the family physician; showing that they can relieve the
symptoms, reduce the demand on attention, improve the
patients’ satisfaction with the given attention and limit the
costs; though with modest results [8]. It is important to
find tools in the psychosocial approach of these patients
added to those already recommended for GCP. The
Cognitive Behavioral Therapy (CBT) or the psycho-
dynamic psychotherapy has been useful in the field of
secondary medical care [9-11]. In a recent systematic
review of the 34 analyzed RCTs on interventions in soma-
toform symptoms, only 9 are developed in primary care
[12]. In these nine RCTs conclude significant results in
the decrease of use of services [13-16], improvement
on physical and/or psychical performance [17-20]. The
reattribution technique specifically designed by Goldberg
and Cols [21] is used in two of the analyzed studies for the
treatment of somatization in primary care through the
teaching and training of family physicians. Their results
show low improvement on the physical symptoms [22,23]
but there is a significant decrease in the prescription of
analgesic medication (8.1%-23%) and anti-depressants
(11.3%-26.9%). The interventions carried out by nursing
professionals are effective, but they are excessively ex-
pensive in terms of number of sessions (at least 12) and
in the required training time (80 hours) [8].
An alternative for the treatment of this kind of disorder
in the field of primary care could be group interventions
with a limited number of sessions. Martin A et al [24] carry
out an RCT that assessed the effectiveness of a single cog-
nitive-behavioral group session (relaxation and motivation
technique to take physical exercise) in order to improve
the approach of the patient to the symptoms, by means
of their explanation from a non- biologist focus. They
found a significant reduction in the seriousness of the
Table 1 Somatoform disorders classification
International Classification
of Diseases, 10th version
(ICD-10)
Diagnostic and Statistical
Manual of Mental
Disorders, 4th Edition
(DSM-IV)
F45 Somatoform disorders Somatoform disorders
F45.0 Somatization disorder 300.81 Somatization disorder
F45.1 Undifferentiated
somatoform disorder
300.82 Undifferentiated
somatoform disorder
F45.2 Hypochondriacal
disorders
300.7 Hypochondriasis
F45.3 Somatoform
autonomic dysfunction
300.7 Body Dysmorphic Disorder
.30 Heart and cardiovascular
system
.31 Upper gastrointestinal
tract
307.8 Pain Disorder Associated
with Psychological Features
.32 Lower gastrointestinal
tract
300.11 Conversion Disorder
.34 Genitourinary system
.38 Other organ or system
F45.4 Persistent somatoform
pain disorder
F45.8 Other somatoform
disorders
F45.9 Somatoform disorder,
unspecified
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physicians (not in the visits to the specialist), reduction in
number of drug (prescriptions) and in the number of days
on sickness absence. This intervention was carried out by
mental health professionals, which limits its external valid-
ity and its implementation in the field of primary care.
A correct approach to these patients by their family
doctor may reduce iatrogenic. The training of primary
care professionals can help to improve care for patients
consulting for MUS.
A model on cognitive-behavioral group intervention,
based on reattribution techniques, carried out through
four group sessions by primary care nurses, together
with the implementation of regulations on GCP, would
be effective for improving quality of life of patients with
MUS.
Aims
The aim of the present work is to determine whether a
cognitive-behavioral intervention group in patients be-
tween 18 and 65 years old with medically unexplained
symptoms, is more effective than routine clinical prac-
tice to improve the quality of life measured by SF-12
questionnaire at one year follow-up.
The secondary objectives are to determine whether a
cognitive-behavioral intervention group with medically
unexplained symptoms, is more effective than routineclinical practice to:
– Improve the quality of life measured by SF-12
questionnaire at 3 and 6 months.
– Reduce the drug consumption.
– Reduce the number of medical consultation.
– Reduce the days of sickness absence.
– Raise the perception on improvement (standardized
global vision) from the patient's point of view (PGI-I
questionnaire) and from the doctor’s (with the CGI-I).
Methods/Design
Design of the study
This study is a community, parallel clinical trial, randomised
by clusters, that compares cognitive-behavioral intervention
group with routine clinical practice. The intervention will be
carried out by health professionals in 14 Primary Health Care
Centres (PHCCs), in Madrid (Spain).
The randomization units will be the PHCCs (clusters).
The units of analysis will be the patients between 18 and
65 years old with MUS who have seeked medical attention
in PHCCs at least 10 times over the past year. The design by
clusters minimised possible contamination effects between
centres.
Subjects of the study
Adult patients between 18 and 65 years old with MUS,
defined by the occurrence of two or more symptoms during
the last 6 months without any evidence of organic disease
that could explain them, and who have seeked medical at-
tention in primary care at least 10 times during the last year.
1) Inclusion criteria. All patients were required to be:a. Be able to meet the demands inherent to the trial,
i.e, to have no intention of moving, to be reachable
for the next year, and to have the capacity to
understand the questionnaires presented
b. Give signed informed consent to be included in
the study, and to meet no exclusion criterion.
2) Exclusion criteria.
a. Diagnosis of severe mental disorder.
b. Suicidal ideation at the time involved in the
study.
c. Diagnosis of addiction to toxic substances.
d. Diagnosis of organic disease responsible for the
symptoms.
e. Previous psychotherapy during the previous year.
Randomisation
The randomization unit will be the PHCC. An independent
statistician will randomly assign the 14 PHCCs (7 centres
Table 2 Regulations on good clinical practice in the general approach of the patient with medical unexplained
symptoms
1. To plan regular appointments every 4–6 weeks in order to treat them clinically during the first year / 6 months, or if a new symptom
comes up (in worsening periods, appointments could be more frequent).
2. To give the patient a detailed document on the origin of the symptoms
3. To establish high-priority objectives
4. To restrict complementary examinations to the most indispensable ones
5. To control the visits to specialists
6. To have the patient treated by only one doctor
7. To calm down and to reassure
8. To identify the psychosocial stimuli that are involved as well as their link to the worsening of the symptomatology
9. To avoid ambiguous information about the findings that come up
10. To avoid spurious diagnostics
11. Not to treat what the patients do not suffer from
12. To avoid dichotomy explanations, i.e. (mental-physical nature)
13. To mediate, when possible, in their psychosocial problems
14. The best policy is to be sincere on the reports
15. To approach some problems in a multidisciplinary way
16. To organize the management/treatment of the difficult cases
17. To be consistent with the approaches
18. To properly remit to the psychiatry services
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group following a simple, computer-generated random
sequence (Epidat 3.1 software).
Consecutive patients will be chosen to minimize the
risk of bias in their selection.
During consultations, patients will be informed about
the study and asked whether they would like to take part.
Those who accept will be asked to give their signed con-
sent, and checks were made to ensure they met all inclu-
sion criteria but no exclusion criteria.
Sample size
Method of calculation For an alpha of 0.05, a power of
80%, and in order to detect an increase of 20% in the pro-
portion of patients that improve at least 4 points on area of
mental healthcare of the SF-12 questionnaire (50% in the
intervention group and 30% in the control group), the over-
all sample size required is 206 patients (103 in each arm of
the study).
Since randomization is by clusters, the sample size had
to be larger than if simple randomisation had been per-
formed, in order to take into account the design effect.
The intra-class correlation coefficient is 0.01 [25,26] and a
mean cluster size is assumed to be 8 patients. The design
effect is 1.07. Given these assumptions, and expecting a
10% loss rate at one year, the final sample size required is
242 (121 in each arm).Masking
In a study of this type it is impossible to mask the interven-
tion. The analysis data will be performed by independent
professionals blinded to the assignment group.
Intervention:
a. In the control group:
Routine clinical practice: The clinical approach of the
patients will be done following the recommendations of
clinical practice guidelines as detailed in Table 2.
b. In the intervention group:
Besides the routine clinical practice, four weekly cognitive-
behavioral group sessions of 2 hours guided by nurse profes-
sionals will be carried out in the PHCC. The groups will be
made up by 6–12 patients.
The content of the sessions will be as follows (Table 3):
If the study results prove that the intervention is ef-
fective, cognitive behavioral sessions are planned for the
patients in the control group.
Before starting the intervention itself, will develop the
training for professionals involved in the study. In order to
make the best use of the diagnosis and the therapeutic
approach on the patients that have been identified as suf-
fering from anxiety and/or depression disorders, and to
standardize clinical practice, a two-hour initial training
Table 3 Structure of the group sessions in the intervention group
1. COGNITIVE REATTRIBUTION
• Psychological explanation of the symptoms: To explain the objective of the session that is not precisely to heal the symptoms, but rather
“to improve doping". To explain that somatization is a common phenomenon resulting from different factors and mechanisms. The patients
are asked to talk about the different factors; and stress is introduced as an explanatory element of the symptoms.
• The importance of the cognitive issue. They give examples on the role of knowledge and the patients are asked to link them to their own
experiences. The objective is to show how the behaviors and the attitude toward the symptoms could change the response to them.
2. RELAXATION AND SYMPTOMATIC RELIEF
• Once the role of stress in the genesis of pain has been described, techniques are introduced where physical exercising and muscular
relaxation are combined. The patients are provided with a CD with spoken instructions.
3. BEHAVIOR-ILLNESS
• The patients are given details on optional treatments and on the correct use of sanitary services. They are also instructed on the mechanisms
to control anomalous behavior toward the illness.
4. AEROBIC EXERCISING
• To encourage physical exercising: to do away with the bad habit of stating that “pain stops me from doing any kind activity” thus, they avoid
doing any kind of activity. An ongoing program on physical exercising is outlined.
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pate in the study. The session will have the following con-
tent: train in the use of the PRIME-MD questionnaire; as
well as in upgrading the rules on pharmacological treat-
ment of the detected pathologies. In addition will be
reviewed Standards for GCP for approaching the patients
with MUS (Table 2).
Besides, there will be a ten-hour specialized training ses-
sion aimed to the nurses in charge of perform the interven-
tion at each center, reattribution techniques and cognitive-
behavioral, that underlie the intervention group.
Data collection method
The doctor will recruit the patients and will assess the
selection criteria. He will let the patient know about the
objectives of the study; and will request his informed
consent.
All patients who accepted to participate will get the
SF-12 questionnaire on quality of life at the end of the
doctor’s examination. Furthermore, all patients will get
the PRIME-MD questionnaire to identify any psychiatric
co-morbidity that will be treated by the doctor according
to his criterion.
At 3, 6 and 12 months (visits V2, V3 and V4, respect-
ively) will be referred the patient to evaluate the useful-
ness of cognitive-behavioral sessions, and completion of
quality of life questionnaire (SF-12) and Clinical Global
Impression of patient and physician (PGI and CGI).
The structure of the study is described in Table 4.
Variables
Outcomes variables
The main outcome variable is the improvement in 4 or
more points in the area of Mental Healthcare from the SF-
12 Quality of life at 12 months. The Spanish version of this
Questionnaire has been validated: high inner consistency
(range 0.77-0.92) for all the dimensions, except social
function (0.55). The questionnaire is self-administered.The secondary outcome variables recorded are:
– Questionnaire on Global Clinical Impression. Used
to assess the patient's (PGI questionnaire) and the
doctor’s (CGI Questionnaire) perceptions on the its
improvement with the interventions. Will be
administered at 6 months (to assess the effectiveness
of the rules of good clinical practice) and at
12 months to evaluate the effectiveness of the
intervention group added to the standards of good
clinical practice. Will be treated as ordinal
qualitative variable.
– Quality of life at 3 and 6 months after the
intervention measured by the SF-12 questionnaire.
– Number of consultations during the period of study
(broken down between nursing and medicine, each
group session will be counted as a nursing
consultation).
– Prescribed medicine during the period of study, with
doubtful therapeutic value for their processing;
related to the MUS. The included medicines are
those related to the functional symptomatology:
– Pain: analgesic medicines, Nonsteroidal Anti-
inflammatory Drugs and muscular pain
reliever.
– Dizziness: vestibular sedatives, peripheral brain
and vasodilators.
– Digestive Symptoms: pro-kinetics, anti-emetics.
– Asthenia: vitamin complex, restoratives, derived
from ginseng, appetite stimulants.
– Anxiety: anxiolytics, antidepressants.
It will be regarded as quantitative variable, defined as
the number of medicine taken during the period of
study.
– Days of sickness absence during the period of study.
Table 4 Project structure
Intervention Group Control Group
Recruitment visit (V 0) Selection criteria
Consecutive selection Request on informed consent
PRIME MD Questionnaire
Variables:
• SF-12 Questionnaire on life quality
• Descriptive variables: sex, cultural level, age,
months with symptoms, time on
antidepressants consumption, requested tests y
specialized derivations to
Training of
professionals
involved
Training in management of PRIME-MD survey.
Review of Standards of Good Clinical Practice
Training in cognitive-behavioral
(Only intervention Group)
Baseline visit (V1) Variables:
• SF-12 Questionnaire
• Prescribed medicine
• Requested tests
• Derivations to secondary level
• Days of sickness absence
• Assessment of compliance with the standards
of good clinical practice
• Questionnaire on global clinical impression;
both, the doctor and the patient
Intervention There will be a weekly group
session for 4 weeks (Only
intervention Group)
Routine clinical practice
3-months post
Intervention visit (V2)
Variables:
• SF-12 Questionnaire
• Prescribed medicine
• Requested tests
• Derivations to secondary level
• Days of sickness absence
• Assessment of compliance with the standards
of good clinical practice
• Questionnaire on global clinical impression;
both, the doctor and the patient
• Assessment by the nurse
subject participation.
• Assessment of cognitive-
behavioral module by subject
(Only intervention Group)
6-months post
Intervention visit (V3)
12-months post
Intervention visit (V4)
Variables:
• SF-12 Questionnaire
• Prescribed medicine
• Requested tests
• Derivations to secondary level
• Days of sickness absence
• Assessment of compliance with the standards
of good clinical practice
• Questionnaire on global clinical impression;
both, the doctor and the patient
• Assessment of cognitive-
behavioral module by subject
(Only intervention Group)
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– Duration of the somatic symptoms before the study.
Quantitative variable (number of months).– Time on anti-depressants consumption (months)
before the study.
– Psychiatric Co-morbidity at the beginning of the
study. It will be analyzed as a dichotomy
qualitative variable (yes/no); assessing the
presence/absence of depression, anxiety and
somatic-morph disorders (according to the PRIME
MD classification).
– PRIME-MD questionnaire; validated in Spain [27]
that categorizes the patient into 5 areas of mental
disorders with greater incidence on primary care:
disorders in the state of mind/mood, anxiety
disorders, disorders on nutritional behavior,
somatoform disorders and disorders due to
alcohol abuse or addiction. There are two
components: a questionnaire for the patient that
acts as a sifting/testing tool, and an assessment
guide for the doctor that allows the diagnostic
confirmation on the case. Once the questionnaire
has been carried out, the patients diagnosed
under anxiety or depression will be treated in a
standardized way. Thus a bias is eliminated in the
understanding of the study results, i.e. not to have
treated the identified anxious-depressive
psychiatric co-morbidity in a proper way; an issue
that could have positive effect on the somatoform
manifestations.
– Derivations carried out at secondary level.
– Complementary Tests, grouped in the following
categories: laboratory, image tests, and
endoscopies.Sociodemographics descriptive variables
Age, sex, cultural level, labor status on date of inclusion
into the study.Withdrawal
Subject withdrawal criteria
a. The appearance of a pathological condition to
explain the symptoms.
b. The use of an unusual alternative therapy (other
than those normally used by the patient) for the
treatment of symptoms, such as psychotherapy, etc.
that could alter the outcome.
c. If the patient shows his/her desire to withdrawing
from the study.
d. If the patient does not come to the follow-up visits.
If any of these events take place, it will be registered
on the Case Report Form (CRF); stating clearly the date
and the reason. The data will be equally processed to
allow the analysis with intention to treat.
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The use of randomization by clusters conditions the
statistical analysis that can be employed, especially
in the calculation of confidence intervals and the
testing of hypotheses. The following analyses will be
undertaken:
1. Descriptive analysis of each variable with its
corresponding CI at 95%. Description of the profile
of patients who abandoned the study plus their
reason for withdrawal.
2. Baseline comparison of the two intervention groups
in terms of the variables measured, prognostic
factors and descriptive variables. Bivariate statistical
tests will be used depending on the type of variable
(qualitative or quantitative one).
3. Analysis of primary outcome: comparison of the
proportion of patients that improve in 4 or more
points in the area of Mental Healthcare from the
SF-12 in both groups, at 12 months after patient
inclusion, using the Chi-squared test, and the
calculation of confidence intervals 95%. Logistic
regression with random effects will be used to
adjust for prognostic factors; the dependent
variable will be the improvement or not in 4 or
more points obtained in Mental Healthcare; and
the independent variable the intervention group to
which each patient belonged. Confounding factors
or factors that might alter the effect recorded will
be taken into account in this analysis.
4. Analysis of secondary outcomes variables. The
results of the secondary variables according to the
assigned group will be compared for each secondary
response variable using appropriate statistical tests.
All statistical tests will be performed with intention to
treat. The last observation carried forward will be used
for missing data. Significance was set at p< 0.05. All cal-
culations will be made using SPSS© v.18 software.Ethical considerations
The study protocol was approved by the Research Ethics
Committee on October, 29th 2008 and met all good clin-
ical practice demands right. This study has been funded by
the Spanish Ministry of Science and Innovation via the
Instituto de Salud Carlos III (PI08/90707). The trial was
registered with ClinicalTrials.gov, number NCT01484223
[http://ClinicalTrials.gov].Discussion
Resolute treatment of psychological or psychosocial issues
by primary care professionals is a encouraging challenge.
The study incorporates the PRIME MD questionnaire, auseful tool for diagnosing comorbid conditions. The time
for application is 10 minutes. Its sensitivity and specificity
make it a valid tool for the diagnosis of the most prevalent
psychiatric disorders in primary care.
The study design used in this work is, however, subject
to certain limitations. The intervention cannot be masked,
which could influence the assessment of its effect. Cer-
tainly, the possibility of contamination exists if the patients
or professionals involved communicate with one another.
For this reason randomization by clusters was employed.
It was assumed that the number of clusters was sufficient
for the random assignment of PHCCs to one arm or the
other to compensate for such potential confounding
factors.
To mask the analysis of data, the persons charged with
this task were blind to the arm to which each health care
center had been assigned.
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PHCC Boadilla del Monte (Boadilla del Monte): Mª Fe Prádana Martínez,
Lourdes Del Santo Mora, Ángeles García Pindado, Nuria Ruiz Hombrebueno.
Rosario Beltrán Álvarez, Ana Isabel Aguilar Gutiérrez, José Luis Mota
Rodríguez, Rafael Cosculluela Pueyo.
PHCC Pozuelo Estación (Pozuelo de Alarcón): José Mª Fernández-Bravo
Álvarez, María Lacalle Rodríguez-Labajo, Diana Pitarch Velasco, Celia García
López, Irene Ayuso Olmedo. Rosa Bonilla Sánchez, Mª Carmen Artieda-
González-Granda, Raquel Razola Rincón.
PHCC Sierra de Guadarrama (Collado Villalba): Mª Gloria Heras Salvat. Mª
Ángeles Sánchez de la Ventana, Concepción Martínez Guinea, Luis Huerta
Galindo, Ana Belén Barrio Ovalle, Susana Miguel Martin, Paz Portero Fraile.
PHCC Mª Jesús Hereza (Leganés): Teresa Rollán Landeras, Mª Jesús Bedoya
Frutos, Mª Angeles Rollán Hernández.
PHCC Huerta de los Frailes (Leganés): Inmaculada Muñoz Sánchez,
Francisco Gutiérrez Ruiz, Susana Menéndez Álvarez.
PHCC Francia (Fuenlabrada): Julia Sánchez Miró. Higinio Pensado Freire
(HP).
PHCC Loranca (Fuenlabrada): Arturo Rodríguez Cardoso, Mª José Rojas
Giraldo. Marisa Herrera Garcia.
PHCC Valdezarza (Madrid): Eva Muro Díaz, Dolores Reguera de Castro,
Paloma Rius Fortea. Inés Gómez García, Nuria Llamas Sandino, Isabel López
Borja, Hortensia Maldonado Castro.
PHCC Villanueva de la Cañada (Villanueva de la Cañada): Cristina López
Menéndez, Juana Blasco Albert.
PHCC Pozuelo San Juan (Pozuelo de Alarcón): Alicia Díaz Revilla, Fernando
León Vázquez, Pilar Burón Martínez, Beatriz Fandiño García, Pedro Pablo
Iglesias Dorado, Mª José Rey Álvarez.
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